Pfizer Products Inc

In the matter of Pfizer Products Inc, the applicant, the respondent was the Commissioner of Patents. The dispute concerned the patentability of a pharmaceutical product, specifically a method of treating erectile dysfunction.

The primary legal issue before the court was whether the claims in Pfizer's patent application, which described a method of treating erectile dysfunction using sildenafil citrate, were valid and ought to be granted. This involved determining whether the claimed invention was novel, involved an inventive step, and was capable of industrial application, as required by the Patents Act 1990 (Cth).

Justice Terry Williams considered the evidence presented by both parties, including expert testimony regarding the prior art and the technical efficacy of the claimed method. The court applied the principles of patent law, particularly concerning the assessment of inventiveness in the context of pharmaceutical compounds and their therapeutic uses. The court found that the invention, as claimed, did not meet the threshold for inventiveness over the existing knowledge at the time of filing.

Consequently, the court dismissed Pfizer's application for the patent, upholding the Commissioner's decision.